S. Hacein-Bey describes the history of gene therapy, the triumphs and failures of ex vivo gene transfer technology in hereditary diseases, the development of chimeric antigen receptor (CAR) T cell therapy for cancer, and the exciting opportunities that are emerging with new gene editing technologies such as CRISPR.

Summary

Introduction : Definitions & Objectives of the colloquium: Selective choices among relevant areas with established therapeutic progress. Dominique BELLET et Jean-Paul TILLEMENT

New diagnostic and Therapeutic Technologies

Integration of individual genetic and kinetic characteristics for the pharmacological optimization of drug use. Pierre MARQUET

Toward precision medicine for age-related diseases: standardized geriatric assessment. Fati NOURHASHEMI

Genomic and precision medicine: setting problems and perspectives. Francis GALIBERT

Managing drug interactions: a clinical decision support system. Jacques TURGEON

Therapeutic targeting of Interleukin 17: An example of translational medicine. Pierre MIOSSEC

Realities and perspetives of precision medicine

Type 2 diabetes and hypercholesterolemia. André SCHEEN

Should we sequence each patient's tumour?  Christophe LE TOURNEAU

Kidney transplantation: an emblematic example of precision medicine to solve an increasingly complex situation. Thierry HAUET

Gene, cellular and stem-cell therapies: perspectives and limits. Salima HACEIN-BEY

Precision Medicine: which applications, cost and targeted populations? Jean-Pierre MICHEL

Organizers
Pr Dominique Bellet, Pr Jean-Paul Tillement
Authors
Salima Hacein-Bey-Abina, Paris
Organizers
Pr Dominique Bellet, Pr Jean-Paul Tillement
Authors
Salima Hacein-Bey-Abina, Paris
Category
The patient
Publication type
Proceedings
Year
2017
Download the publication